Global Ankylosing Spondylitis Market 2015-2019
About Ankylosing Spondylitis
Ankylosing spondylitis is a subtype of spondylarthropathy. The primary symptoms of the disease are inflammatory spinal pain with subsequent limitation of spine mobility and chest expansion. Ankylosing spondylitis can be diagnosed using clinical signs, radiological signs (sacroiliitis) and the presence of HLA-B27 antigen. According to the NIH and NIAMS, ankylosing spondylitis is a type of arthritis, which affects the joints in the vertebral column severely. It is a progressive inflammatory disease that typically becomes evident during early to mid-adulthood, as per NORD. It can also lead to the loss of spinal mobility for the affected individuals. The cause of the disease is not known, however, the HLA-B27 gene plays a major role. Ankylosing spondylitis is hereditary in nature.
TechNavio's analysts forecast the Global Ankylosing Spondylitis market to grow at a CAGR of 5.05 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Ankylosing Spondylitis market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of ankylosing spondylitis. The market is segmented based on the mechanism of action of the drugs used to treat ankylosing spondylitis as illustrated below:
TechNavio Announces the Publication of its Research Report – Global Ankylosing Spondylitis Market 2015-2019
TechNavio recognizes the following companies as the key players in the Global Ankylosing Spondylitis Market: Abbvie Inc., Amgen Inc., Janssen Pharmaceuticals Inc., Merck & Co. Inc. and Pfizer Inc.
Other Prominent Vendors in the market are: Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eisai, F. Hoffmann-La Roche, Merck Sharp & Dohme, Novartis, Otsuka Pharmaceutical, Regeneron Pharmaceuticals, Sanofi, Shanghai Pharmaceuticals and UCB.
Commenting on the report, an analyst from TechNavio’s team said: “The dominance of the market by biologics for the treatment of patients suffering from ankylosing spondylitis is one key trend in the market. Biologics are expected to be a preferred treatment option among the medical fraternity, patients, and the families of patients during the forecast period. This increases the number of treatment-seeking patients, which increases the overall consumption of medicines.”
According to the report, presence of high unmet needs in terms of appropriate drugs is one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely, and the drugs have a low safety profile, resulting in a rate high mortality. Therefore, drugs that can cause disease remission in patients and have a high safety profile are expected to drive the growth of the market.
Further, the report states that expiry of patents is one of the major challenges hindering the growth of the market. Loss of patents of major drugs used in treatment of ankylosing spondylitis is expected to lower their revenue share, leading to a decrease in the overall revenue of the vendors in the market.Abbvie , Amgen , Janssen Pharmaceuticals , Merck & Co. , Pfizer , Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eisai, F. Hoffmann-La Roche, Merck Sharp & Dohme, Novartis, Otsuka Pharmaceutical, Regeneron Pharmaceuticals, Sanofi, ShanghaiPharmaceuticals, UCB
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook